A single dose of CBD brought social anxiety patients' public speaking anxiety down to the level of people without anxiety disorders

Twenty-four treatment-naive SAD patients were randomized to CBD 600 mg (n=12) or placebo (n=12), with 12 healthy controls. CBD significantly reduced anxiety (p=0.012), cognitive impairment (p=0.009), and discomfort (p=0.029) during public speaking versus placebo. Negative self-statements were "almost abolished" by CBD. No significant differences between CBD and healthy controls on most measures (SSPS-N, cognitive impairment, discomfort, alertness subscales of VAMS). Statistical power: 0.996 for primary anxiety measure.

Double-blind, randomized, placebo-controlled study with healthy control group. 2,319 undergraduates screened with MINI-SPIN; 24 treatment-naive SAD patients confirmed by SCID-CV. CBD group received 600 mg (~99.9% pure) in gelatin capsules 90 min before Simulated Public Speaking Test (4-min speech, videotaped). Measured: Visual Analogue Mood Scale (VAMS — 4 factors), Negative Self-Statement Scale (SSPS-N), Bodily Symptoms Scale (BSS), heart rate, blood pressure, skin conductance at 6 time points. FAPESP-funded. Repeated-measures ANOVA with Bonferroni correction.

This study provided the clearest evidence to date that CBD could normalize clinical anxiety to healthy control levels without sedation or cognitive impairment — differentiating it from benzodiazepines. Combined with companion neuroimaging showing CBD reduces limbic brain activity, it established CBD as a serious anxiolytic candidate with a plausible mechanism. It became the foundational citation for the entire CBD anxiety research field and the CBD wellness market.

Bergamaschi 2011 is the most cited single study supporting CBD for anxiety, but the field has been slow to advance beyond it. No completed large-scale RCT of repeated CBD dosing for clinical anxiety disorders exists as of 2026. The gap between this proof-of-concept (600 mg pharmaceutical-grade, single dose, lab setting) and real-world use (low-dose consumer products for daily anxiety) remains largely unstudied.

Only 12 patients per group. Single-dose study with no information on repeated dosing, tolerance, or durability. 600 mg dose is impractical and expensive for real-world use. Simulated public speaking does not capture daily social anxiety. Young Brazilian university student sample limits generalizability. Treatment-naive patients may respond differently than typical treatment-seeking patients. No adverse event power with 12 subjects.